Market Overview:
The global heparin-induced thrombocytopenia (HIT) treatment market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of HIT and rising demand for better diagnostic tests for early diagnosis and treatment of HIT. Based on type, the global heparin-induced thrombocytopenia (HIT) treatment market is segmented into enzyme immunoassay (EIA), serotonin release assay (SRA), enzyme-linked immunosorbent assay (ELISA), and heparin-induced platelet activation test (HIPA). The ELISA segment is expected to account for the largest share of the global heparin-induced thrombocytopenia treatment market in 2018. This can be attributed to its high accuracy and sensitivity as compared to other types of tests available in the market. Based on application, hospitals are estimated to account for the largest share of the global heparin induced thrombocytopenia Treatment Market in 2018. This can be attributed to increasing number of patients suffering from HIT across hospitals worldwide.
 Treatment Industry Outlook.svg)
Product Definition:
Heparin-induced thrombocytopenia (HIT) is a disorder that can occur after you receive heparin, a drug used to prevent blood clots. HIT can cause dangerous blood clots to form in your body.
Enzyme Immunoassay (EIA):
Enzyme Immunoassay (EIA) is a technique that involves the use of enzymes, which are catalysts for the conversion of inactive substances into active ones. These techniques have been used as an immunological test since it helps in detecting and measuring antibodies by using specific enzymes. Enzymes such as proteases, lipases or phospholipase are used to measure and detect various substances including antigens, hormones, drugs etc.
Serotonin Release Assay (SRA):
The serotonin release assay (SRA) is a new diagnostic test for the detection of platelet-derived serotonin in patients with HIT. The SRA has advantages over other tests such as PFA and tryptase because it can be performed without specialized laboratory equipment, provides results within 15 minutes, and does not require trained professionals to operate.
Application Insights:
Based on application, the market is segmented into hospitals, diagnostic centers, specialty clinics and emergency ambulatory centers. Hospitals held the largest share of over 70.0% in 2017 owing to availability of advanced healthcare facilities along with a high number of thrombocytopenic patients admitted in hospitals every year.
Furthermore, increasing awareness among individuals regarding available treatment options and growing adoption of these tests by hospitals are some factors that may drive the segment during the forecast period.
Regional Analysis:
Europe dominated the global HIT market in terms of revenue share in 2016. The presence of well-established healthcare facilities, favorable government initiatives, and increasing awareness about blood disorders are some factors responsible for its large share. Moreover, a rise in the number of clinical trials for various diseases is also expected to drive this regional market over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to an increase in patient pool and subsequently rising incidence rates of cardiovascular diseases (CVDs). This can be attributed to unhealthy lifestyles and growing economic conditions that enable people indulge themselves with food & beverages high fat content which increases CVD risk factors such as hypertension & obesity. These aforementioned factors are expected boost demand for HIT testing products over the next eight years.
Growth Factors:
- Increasing incidence of HIT
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for HIT patients
- Technological advancements in the field of heparin-induced thrombocytopenia treatment 5. Availability of government funding for research on new treatments for HIT
Scope Of The Report
Report Attributes
Report Details
Report Title
Heparin-Induced Thrombocytopenia (HIT) Treatment Market Research Report
By Type
Enzyme Immunoassay (EIA), Serotonin Release Assay (SRA), Enzyme-Linked Immunosorbent Assay (ELISA), Heparin-Induced Platelet Activation (HIPA) Test
By Application
Hospitals, Diagnostic Centers, Specialty Clinics, Emergency Ambulatory Centers
By Companies
Pfizer Inc., Eagle Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
131
Number of Tables & Figures
92
Customization Available
Yes, the report can be customized as per your need.
Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Report Segments:
The global Heparin-Induced Thrombocytopenia (HIT) Treatment market is segmented on the basis of:
Types
Enzyme Immunoassay (EIA), Serotonin Release Assay (SRA), Enzyme-Linked Immunosorbent Assay (ELISA), Heparin-Induced Platelet Activation (HIPA) Test
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic Centers, Specialty Clinics, Emergency Ambulatory Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc.
- Eagle Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline Plc.
 Treatment Market Overview.svg)
Highlights of The Heparin-Induced Thrombocytopenia (HIT) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enzyme Immunoassay (EIA)
- Serotonin Release Assay (SRA)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Heparin-Induced Platelet Activation (HIPA) Test
- By Application:
- Hospitals
- Diagnostic Centers
- Specialty Clinics
- Emergency Ambulatory Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Heparin-Induced Thrombocytopenia (HIT) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Heparin-induced thrombocytopenia (HIT) is a condition in which the body does not produce enough platelets. Platelets are small blood cells that help prevent bleeding. HIT can be caused by taking heparin, a medication used to prevent blood clots, or by having surgery. Treatment for HIT includes stopping the heparin and getting regular blood tests to check on your platelet count. If your platelet count falls below a certain level, you may need treatment with clotting factors or other medications to help your body make more platelets.
Some of the major companies in the heparin-induced thrombocytopenia (hit) treatment market are Pfizer Inc., Eagle Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc..
The heparin-induced thrombocytopenia (hit) treatment market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Heparin-Induced Thrombocytopenia (HIT) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Heparin-Induced Thrombocytopenia (HIT) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size & Forecast, 2018-2028
4.5.1 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size and Y-o-Y Growth
4.5.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Absolute $ Opportunity
Chapter 5 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
5.2.1 Enzyme Immunoassay (EIA)
5.2.2 Serotonin Release Assay (SRA)
5.2.3 Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.4 Heparin-Induced Platelet Activation (HIPA) Test
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic Centers
6.2.3 Specialty Clinics
6.2.4 Emergency Ambulatory Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
9.6.1 Enzyme Immunoassay (EIA)
9.6.2 Serotonin Release Assay (SRA)
9.6.3 Enzyme-Linked Immunosorbent Assay (ELISA)
9.6.4 Heparin-Induced Platelet Activation (HIPA) Test
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic Centers
9.10.3 Specialty Clinics
9.10.4 Emergency Ambulatory Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
10.6.1 Enzyme Immunoassay (EIA)
10.6.2 Serotonin Release Assay (SRA)
10.6.3 Enzyme-Linked Immunosorbent Assay (ELISA)
10.6.4 Heparin-Induced Platelet Activation (HIPA) Test
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic Centers
10.10.3 Specialty Clinics
10.10.4 Emergency Ambulatory Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
11.6.1 Enzyme Immunoassay (EIA)
11.6.2 Serotonin Release Assay (SRA)
11.6.3 Enzyme-Linked Immunosorbent Assay (ELISA)
11.6.4 Heparin-Induced Platelet Activation (HIPA) Test
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic Centers
11.10.3 Specialty Clinics
11.10.4 Emergency Ambulatory Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
12.6.1 Enzyme Immunoassay (EIA)
12.6.2 Serotonin Release Assay (SRA)
12.6.3 Enzyme-Linked Immunosorbent Assay (ELISA)
12.6.4 Heparin-Induced Platelet Activation (HIPA) Test
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic Centers
12.10.3 Specialty Clinics
12.10.4 Emergency Ambulatory Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Heparin-Induced Thrombocytopenia (HIT) Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Type
13.6.1 Enzyme Immunoassay (EIA)
13.6.2 Serotonin Release Assay (SRA)
13.6.3 Enzyme-Linked Immunosorbent Assay (ELISA)
13.6.4 Heparin-Induced Platelet Activation (HIPA) Test
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic Centers
13.10.3 Specialty Clinics
13.10.4 Emergency Ambulatory Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Competitive Dashboard
14.2 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer Inc.
14.3.2 Eagle Pharmaceuticals Inc.
14.3.3 Teva Pharmaceutical Industries Ltd.
14.3.4 GlaxoSmithKline Plc.
